Joseph C. Resch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph C. Resch has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Srinath Chinnakotla
Department of Surgery University of Minnesota Medical School Minneapolis Minnesota USA
3 shared publications Alexandra Monde
Department of Pediatrics Georgetown University Hospital Washington D.C. USA
2 shared publicationsArif Somani
Department of Pediatric Critical Care, University of Minnesota, M Health Fairview Masonic Children’s Hospital, Minneapolis, MN, United States
2 shared publicationsElise Kang
Department of Pediatrics Columbia University Irving Medical Center New York USA
2 shared publicationsFernando Beltramo
Department of Anesthesiology Critical Care Children's Hospital of Los Angeles Los Angeles USA
2 shared publicationsGwenyth Fischer
Department of Pediatrics University of Minnesota Medical School Minneapolis Minnesota USA
2 shared publications
Latest Publications
- Open Access
- 21 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70380
ABO Incompatible Deceased Donor Liver Transplants in Infants (Age < 1 Year): A Single‐Center Experience
Background: The liver transplant waitlist mortality for infants (age < 1 year) is currently the highest, listed at 20 per 100 years of waiting time. ABO incompatible (ABOi) liver‐transplantation is one of the strategies to increase transplantation rate in infants but utilized only in 5.6% of infants. Methods: At our center, all children < 1 year are listed for ABOi liver transplants. If the anti‐ABO titers are less than 1:8, no plasmapheresis was used. Thymoglobulin is used for induction. We analyzed the transplant outcomes of patients that received ABOi livers compared to ABOc livers. Results: Sixteen infants, who received ABOi liver‐transplants are compared to 56 ABO‐compatible (ABOc) infant liver transplants. ABOi group utilized AB or B blood type livers 81%, compared to none in the ABOc group. The 1‐, 5‐, and 10‐year survival in the ABOi group remains at 81% and is comparable to survival in the ABOc group. None of the ABOi patients developed antibody‐mediated rejection or intrahepatic biliary strictures. None of the ABOi patients had hepatic artery thrombosis, compared with 4 (7.1%) in the ABOc group ( p = 0.64). There is no difference in infectious complications. The median wait times for patients < 1 year for blood types A, B, AB, and were 96, 109, 82 days and 126 respectively. The patients listed to accept ABOi livers had a shorter waiting time ( p = < 0.001). Conclusions: This study shows that ABOi liver transplants can be safely performed in children less than1 year of age without plasmapheresis, with excellent long‐term outcomes.
- 21 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70380
Open AccessABO Incompatible Deceased Donor Liver Transplants in Infants (Age < 1 Year): A Single‐Center Experience
Background: The liver transplant waitlist mortality for infants (age < 1 year) is currently the highest, listed at 20 per 100 years of waiting time. ABO incompatible (ABOi) liver‐transplantation is one of the strategies to increase transplantation rate in infants but utilized only in 5.6% of infants. Methods: At our center, all children < 1 year are listed for ABOi liver transplants. If the anti‐ABO titers are less than 1:8, no plasmapheresis was used. Thymoglobulin is used for induction. We analyzed the transplant outcomes of patients that received ABOi livers compared to ABOc livers. Results: Sixteen infants, who received ABOi liver‐transplants are compared to 56 ABO‐compatible (ABOc) infant liver transplants. ABOi group utilized AB or B blood type livers 81%, compared to none in the ABOc group. The 1‐, 5‐, and 10‐year survival in the ABOi group remains at 81% and is comparable to survival in the ABOc group. None of the ABOi patients developed antibody‐mediated rejection or intrahepatic biliary strictures. None of the ABOi patients had hepatic artery thrombosis, compared with 4 (7.1%) in the ABOc group ( p = 0.64). There is no difference in infectious complications. The median wait times for patients < 1 year for blood types A, B, AB, and were 96, 109, 82 days and 126 respectively. The patients listed to accept ABOi livers had a shorter waiting time ( p = < 0.001). Conclusions: This study shows that ABOi liver transplants can be safely performed in children less than1 year of age without plasmapheresis, with excellent long‐term outcomes.
- 1 February 2026
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 22 (1) , 91-110
Post-operative opioid consumption in pediatric solid organ transplant recipients: A single-site retrospective evaluation
Background: There is a paucity of data depicting post-operative opioid consumption in pediatric solid organ transplant (SOT) recipients, limiting ability to perform power analyses in designing prospective trials focusing on analgesia or adjuvant therapies in these populations. There is additionally unclear effect magnitude of various confounders of analgesic and sedative medications encountered in the pediatric intensive care unit (PICU). Methods: Retrospective review of pediatric patients aged 2 months-18 years at a single institution was performed on 137 SOT recipients (cardiac, liver, renal, total pancreatectomy with islet cell autotransplantation [TPIAT]) to evaluate post-operative opioid consumption in the PICU, analgesic confounders, pain scores, and opioid-related adverse effects (constipation, ileus, pruritus, nausea, urinary retention, delirium, respiratory depression, withdrawal). Values for correlative and multiplicative effect magnitude were analyzed for planned variables. Results: Average daily opioid requirement in oral morphine equivalents per kilogram was (cardiac) 12.5 (median 6.98, interquartile range [IQR] 14.3), (liver) 12.6 (median 10.1, IQR 15.3), (renal) 1.47 (median 0.614, IQR 0.95), and (TPIAT) 4.1 (median 3.44, IQR 2.6). Mechanical ventilation dependence, extracorporeal membrane oxygenation use, and open abdomen or chest demonstrated the highest correlation and effect magnitudes with opioid consumption of variables evaluated. No trends were identified for opioid-related adverse effects. Conclusion: Children receiving SOT have high opioid consumption relative to many populations in the PICU. Control for and evaluation of pain confounders such as mechanical ventilation and extracorporeal membrane oxygenation should be utilized in prospective studies analyzing opioid use, adjuvant analgesics, or outcomes in critically ill transplant recipients.
- 1 February 2026
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 22 (1) , 91-110
Post-operative opioid consumption in pediatric solid organ transplant recipients: A single-site retrospective evaluation
Background: There is a paucity of data depicting post-operative opioid consumption in pediatric solid organ transplant (SOT) recipients, limiting ability to perform power analyses in designing prospective trials focusing on analgesia or adjuvant therapies in these populations. There is additionally unclear effect magnitude of various confounders of analgesic and sedative medications encountered in the pediatric intensive care unit (PICU). Methods: Retrospective review of pediatric patients aged 2 months-18 years at a single institution was performed on 137 SOT recipients (cardiac, liver, renal, total pancreatectomy with islet cell autotransplantation [TPIAT]) to evaluate post-operative opioid consumption in the PICU, analgesic confounders, pain scores, and opioid-related adverse effects (constipation, ileus, pruritus, nausea, urinary retention, delirium, respiratory depression, withdrawal). Values for correlative and multiplicative effect magnitude were analyzed for planned variables. Results: Average daily opioid requirement in oral morphine equivalents per kilogram was (cardiac) 12.5 (median 6.98, interquartile range [IQR] 14.3), (liver) 12.6 (median 10.1, IQR 15.3), (renal) 1.47 (median 0.614, IQR 0.95), and (TPIAT) 4.1 (median 3.44, IQR 2.6). Mechanical ventilation dependence, extracorporeal membrane oxygenation use, and open abdomen or chest demonstrated the highest correlation and effect magnitudes with opioid consumption of variables evaluated. No trends were identified for opioid-related adverse effects. Conclusion: Children receiving SOT have high opioid consumption relative to many populations in the PICU. Control for and evaluation of pain confounders such as mechanical ventilation and extracorporeal membrane oxygenation should be utilized in prospective studies analyzing opioid use, adjuvant analgesics, or outcomes in critically ill transplant recipients.
- 11 August 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (6) , e70158
Postoperative Infections and Antimicrobial Prophylaxis in the Pediatric Intensive Care Unit After Liver Transplantation in Children
Objective: To determine the incidence and risk factors for postoperative infections (POI) after pediatric liver transplantation (LT) while in the pediatric intensive care unit (PICU). Methods: This is a multicenter, retrospective cohort study of isolated pediatric LT recipients from 12 LT centers in the United States over 2 years. Pre‐ and postoperative variables were examined to determine POI risk factors during the PICU admission. Antimicrobial prophylaxis utilization was assessed. Comparative statistics were performed using chi‐squared and Mann–Whitney U tests. Multivariable logistic regression modeling evaluated POI risk factors. Results: 76/327 (23%) patients developed POI (47% bacterial, 3% viral, 4% fungal, 22% polymicrobial, and 21% clinically adjudicated, culture negative). Abdominal/surgical site and bloodstream infections were most common at 29% and 26%, respectively. Independent predictors of POI included age under 1 (OR = 2.37 [95% CI 1.36–4.13], p = 0.002), open fascia (OR = 3.15 [95% CI 1.77–5.61], p < 0.001), and hospitalization pre‐transplant (OR = 2.09 [95% CI 1.20–3.64], p = 0.009). Patients with POI had longer hospitalizations (23.0 days [17.0–34.0] vs. 13.0 days [9.0–20.0], p < 0.001), higher graft loss rates (9% vs. 0.4%, p < 0.001), and greater mortality (5% vs. 0.4%, p = 0.01). Significant variability in antimicrobial regimens existed amongst transplant centers. Conclusions: One in five patients developed POI while in the PICU. Predictors of POI included younger age, open fascia, and hospitalization pre‐transplantation. POIs were associated with significant morbidity, including prolonged length of stay, graft loss, and mortality. Future prospective studies are needed to optimize antimicrobial regimens to prevent POI and improve outcomes.
- 11 August 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (6) , e70158
Postoperative Infections and Antimicrobial Prophylaxis in the Pediatric Intensive Care Unit After Liver Transplantation in Children
Objective: To determine the incidence and risk factors for postoperative infections (POI) after pediatric liver transplantation (LT) while in the pediatric intensive care unit (PICU). Methods: This is a multicenter, retrospective cohort study of isolated pediatric LT recipients from 12 LT centers in the United States over 2 years. Pre‐ and postoperative variables were examined to determine POI risk factors during the PICU admission. Antimicrobial prophylaxis utilization was assessed. Comparative statistics were performed using chi‐squared and Mann–Whitney U tests. Multivariable logistic regression modeling evaluated POI risk factors. Results: 76/327 (23%) patients developed POI (47% bacterial, 3% viral, 4% fungal, 22% polymicrobial, and 21% clinically adjudicated, culture negative). Abdominal/surgical site and bloodstream infections were most common at 29% and 26%, respectively. Independent predictors of POI included age under 1 (OR = 2.37 [95% CI 1.36–4.13], p = 0.002), open fascia (OR = 3.15 [95% CI 1.77–5.61], p < 0.001), and hospitalization pre‐transplant (OR = 2.09 [95% CI 1.20–3.64], p = 0.009). Patients with POI had longer hospitalizations (23.0 days [17.0–34.0] vs. 13.0 days [9.0–20.0], p < 0.001), higher graft loss rates (9% vs. 0.4%, p < 0.001), and greater mortality (5% vs. 0.4%, p = 0.01). Significant variability in antimicrobial regimens existed amongst transplant centers. Conclusions: One in five patients developed POI while in the PICU. Predictors of POI included younger age, open fascia, and hospitalization pre‐transplantation. POIs were associated with significant morbidity, including prolonged length of stay, graft loss, and mortality. Future prospective studies are needed to optimize antimicrobial regimens to prevent POI and improve outcomes.
- Open Access
- 13 August 2024
- Published by Wiley in Paediatric and Neonatal Pain
- Vol. 6 (4) , 203-212
Prolonged magnesium sulfate infusion as adjuvant analgesia in postoperative transplant patients in the pediatric ICU: Preliminary results of a feasibility study
The opioid crisis has emphasized identification of opioid‐sparing analgesics. This study was designed as a prospective trial with retrospective control group to determine feasibility for implementing a high‐dose prolonged magnesium sulfate infusion for adjuvant analgesia in the pediatric intensive care unit. Approval was granted for study of children receiving total pancreatectomy with islet cell autotransplantation and liver transplantation ages 3–18 years. Study exclusions were pregnancy, neuromuscular disease, hypersensitivity, preoperative creatinine >1.5 times upper limit normal, arrhythmia or pacemaker presence, and clinician concern. Eleven patients were enrolled between January 2020 and December 2022. Magnesium sulfate bolus (50 mg/kg) followed by intravenous infusion (15 mg/kg/h) was initiated in the operating room and extended postoperatively (maximum 48 h). Serum magnesium levels were monitored serially. To prioritize safety, infusion dose was decreased by 5 mg/kg/h for levels greater than 3.5 mg/dL. Clinical team otherwise followed standard multimodal pain practice. Primary outcome was oral morphine equivalent per kg per day during intensive care course (maximum 7 days). Secondary outcomes focused primarily on magnesium safety, including hemodynamic variables, electrolyte variables, respiratory support, and opioid‐related side effects. There were no serious adverse events. Treatment group trended toward slightly higher intravenous fluid requirement (~1 bolus), however no increase in blood product. Treatment and control groups were otherwise comparable in targeted outcomes and overall adverse event profile. Use of a high‐dose magnesium sulfate infusion protocol for analgesic postoperative use in select transplant recipients appears feasible for continued optimization of study in the PICU.
- 13 August 2024
- Published by Wiley in Paediatric and Neonatal Pain
- Vol. 6 (4) , 203-212
Open AccessProlonged magnesium sulfate infusion as adjuvant analgesia in postoperative transplant patients in the pediatric ICU: Preliminary results of a feasibility study
The opioid crisis has emphasized identification of opioid‐sparing analgesics. This study was designed as a prospective trial with retrospective control group to determine feasibility for implementing a high‐dose prolonged magnesium sulfate infusion for adjuvant analgesia in the pediatric intensive care unit. Approval was granted for study of children receiving total pancreatectomy with islet cell autotransplantation and liver transplantation ages 3–18 years. Study exclusions were pregnancy, neuromuscular disease, hypersensitivity, preoperative creatinine >1.5 times upper limit normal, arrhythmia or pacemaker presence, and clinician concern. Eleven patients were enrolled between January 2020 and December 2022. Magnesium sulfate bolus (50 mg/kg) followed by intravenous infusion (15 mg/kg/h) was initiated in the operating room and extended postoperatively (maximum 48 h). Serum magnesium levels were monitored serially. To prioritize safety, infusion dose was decreased by 5 mg/kg/h for levels greater than 3.5 mg/dL. Clinical team otherwise followed standard multimodal pain practice. Primary outcome was oral morphine equivalent per kg per day during intensive care course (maximum 7 days). Secondary outcomes focused primarily on magnesium safety, including hemodynamic variables, electrolyte variables, respiratory support, and opioid‐related side effects. There were no serious adverse events. Treatment group trended toward slightly higher intravenous fluid requirement (~1 bolus), however no increase in blood product. Treatment and control groups were otherwise comparable in targeted outcomes and overall adverse event profile. Use of a high‐dose magnesium sulfate infusion protocol for analgesic postoperative use in select transplant recipients appears feasible for continued optimization of study in the PICU.
- Open Access
- 3 June 2024
- Published by Sciaccess Publishers LLC in Journal of Anesthesiology and Pain Therapy
- Vol. 5 (2) , 6-9
Commentary: Postoperative Use and Early Discontinuation of Intravenous Lidocaine in Spine Patients
Our author group’s publication Postoperative Use and Early Discontinuation of Intravenous Lidocaine in Spine Patients published in “Spine Deformity” outlines initial results of an intended line of investigation exploring our experience utilizing intravenous lidocaine for improving perioperative pain in posterior lumbar fusion.
- 3 June 2024
- Published by Sciaccess Publishers LLC in Journal of Anesthesiology and Pain Therapy
- Vol. 5 (2) , 6-9
Open AccessCommentary: Postoperative Use and Early Discontinuation of Intravenous Lidocaine in Spine Patients
Our author group’s publication Postoperative Use and Early Discontinuation of Intravenous Lidocaine in Spine Patients published in “Spine Deformity” outlines initial results of an intended line of investigation exploring our experience utilizing intravenous lidocaine for improving perioperative pain in posterior lumbar fusion.
- Open Access
- 19 October 2023
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 12
Vascular thrombosis after pediatric liver transplantation: Is prevention achievable?
- 19 October 2023
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 12
Open AccessVascular thrombosis after pediatric liver transplantation: Is prevention achievable?
- 1 October 2023
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 44 (10) , 551-565
Pediatric Shock Review
Shock occurs when there is energy failure due to inadequate oxygen/glucose delivery to meet metabolic demands. Shock is a leading cause of death and disability in children worldwide. Types of shock include hypovolemic, cardiogenic, distributive, and obstructive. This review provides an overview of the epidemiology, pathophysiology, and clinical signs and symptoms of each of these types of shock, followed by a discussion of advancements in diagnostic tests and tools and management/treatment principles for different categories of shock.
- 1 October 2023
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 44 (10) , 551-565
Pediatric Shock Review
Shock occurs when there is energy failure due to inadequate oxygen/glucose delivery to meet metabolic demands. Shock is a leading cause of death and disability in children worldwide. Types of shock include hypovolemic, cardiogenic, distributive, and obstructive. This review provides an overview of the epidemiology, pathophysiology, and clinical signs and symptoms of each of these types of shock, followed by a discussion of advancements in diagnostic tests and tools and management/treatment principles for different categories of shock.
- 23 August 2023
- Published by Springer Nature in Spine Deformity
- Vol. 12 (1) , 141-148
Postoperative use and early discontinuation of intravenous lidocaine in spine patients
Purpose Our institution employs a multimodal approach to manage postoperative pain after spine surgery. It involves continuous intravenous (IV) lidocaine until the morning of postoperative day two. This study aimed to determine the rate and reasons for early discontinuation of IV lidocaine in our spine patients. Methods We conducted a retrospective chart review and included pediatric patients who underwent ≥ 3-level spine surgery and received postoperative IV lidocaine from November 2019 to September 2022. For each case, we recorded the side effects of IV lidocaine, adverse events, time to discontinuation, and discontinuation rate. Subsequently, we used the same methodology to generate an adult cohort for comparison. Results We included 52 pediatric (18M:34F) and 50 (21M:29F) adult patients. The pediatric cohort’s mean age was 14 years (8–18), and BMI 23.9 kg/m2 (13.0–42.8). The adult cohort’s mean age was 61 years (29–82), and BMI 28.8 kg/m2 (17.2–44.1). IV lidocaine was discontinued prematurely in 21/52 (40.4%) of the pediatric cases and 26/50 (52.0%) of the adult cases (RR = 0.78, p = 0.2428). The side effects noted in the pediatric cases vary, including numbness, visual disturbance, and obtundation, but no seizures. The most common adverse events were fever and motor dysfunction. Conclusion The early discontinuation rate of IV lidocaine use after spine surgery for children in our institution does not differ significantly from that of adults. The nature of the side effects and the reasons for discontinuation between the groups were similar. Thus, the safety profile of IV lidocaine for pediatric spine patients is comparable to adults.
- 23 August 2023
- Published by Springer Nature in Spine Deformity
- Vol. 12 (1) , 141-148
Postoperative use and early discontinuation of intravenous lidocaine in spine patients
Purpose Our institution employs a multimodal approach to manage postoperative pain after spine surgery. It involves continuous intravenous (IV) lidocaine until the morning of postoperative day two. This study aimed to determine the rate and reasons for early discontinuation of IV lidocaine in our spine patients. Methods We conducted a retrospective chart review and included pediatric patients who underwent ≥ 3-level spine surgery and received postoperative IV lidocaine from November 2019 to September 2022. For each case, we recorded the side effects of IV lidocaine, adverse events, time to discontinuation, and discontinuation rate. Subsequently, we used the same methodology to generate an adult cohort for comparison. Results We included 52 pediatric (18M:34F) and 50 (21M:29F) adult patients. The pediatric cohort’s mean age was 14 years (8–18), and BMI 23.9 kg/m2 (13.0–42.8). The adult cohort’s mean age was 61 years (29–82), and BMI 28.8 kg/m2 (17.2–44.1). IV lidocaine was discontinued prematurely in 21/52 (40.4%) of the pediatric cases and 26/50 (52.0%) of the adult cases (RR = 0.78, p = 0.2428). The side effects noted in the pediatric cases vary, including numbness, visual disturbance, and obtundation, but no seizures. The most common adverse events were fever and motor dysfunction. Conclusion The early discontinuation rate of IV lidocaine use after spine surgery for children in our institution does not differ significantly from that of adults. The nature of the side effects and the reasons for discontinuation between the groups were similar. Thus, the safety profile of IV lidocaine for pediatric spine patients is comparable to adults.
- Open Access
- 29 June 2023
- Published by Elsevier in Urology Case Reports
- Vol. 50, 102481
Bilateral nephrolithiasis following ingestion of guaifenesin and dextromethorphan
- 29 June 2023
- Published by Elsevier in Urology Case Reports
- Vol. 50, 102481
Open AccessBilateral nephrolithiasis following ingestion of guaifenesin and dextromethorphan
- Open Access
- 5 January 2023
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 1011171
Hirudotherapy for limb ischemia in the pediatric intensive care unit: A retrospective observational cohort
Background: Acute limb ischemia due to microvascular malperfusion may be refractory to initial therapies. Medicinal leech therapy (hirudotherapy) has been attempted in plastic and reconstructive surgery to improve venous congestion in ischemic flaps; however, there are minimal reports related to ischemia secondary to arterial malperfusion. We evaluated a pediatric cohort from an academic intensive care unit with refractory limb ischemia in whom hirudotherapy was attempted to elucidate its use and outcomes.Method: Institutional patient database was queried to identify pediatric patients (<18 years) who received hirudotherapy in the pediatric critical care unit and met inclusion/exclusion criteria. Patient charts were evaluated for indices including demographics, primary disease, coagulative status, vascular access, vasoactive medication dosing, bleeding, leech use, limb and mortality outcomes. Data was evaluated to identify trends or suspected impact on outcomes.Results: Hirudotherapy was used in 7 patients for limb ischemia, 5 with congenital heart disease, and 2 others with viremic shock. Time to leech application following recognition of ischemia averaged 3 days, with duration of use averaging 3.9 days. Five patients discontinued therapy due to bleeding. Mortality rate was 57%, all secondary to multiorgan failure. In 3 surviving patients, 4 of 5 treated limbs resulted in at minimum partial amputation. Vasoactive-inotropic score tended higher prior to leech application, suggesting a vasoconstrictive pathway for arterial malperfusion. No identifiable trends appeared associated with salvaged limb or adverse effects. Blood loss predictably increased with leech application, as did total transfusion requirement.Conclusion: This case series establishes baseline data for use of hirudotherapy in critically ill children with acute limb ischemia caused by arterial malperfusion. Based on this retrospective cohort, we cannot recommend routine use of hirudotherapy for acute limb ischemia from arterial malperfusion in the pediatric intensive care unit. Application of leeches should be aligned with a protocol defining start and stop parameters, standardized leech utilization, and monitoring for adverse outcomes. Future study would benefit from consensus definitions of study outcomes, including perfusion recovery, tissue/limb salvage and bleeding manifestations. Additional prospective studies are needed prior to any standard or systematic recommendations for use.
- 5 January 2023
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 1011171
Open AccessHirudotherapy for limb ischemia in the pediatric intensive care unit: A retrospective observational cohort
Background: Acute limb ischemia due to microvascular malperfusion may be refractory to initial therapies. Medicinal leech therapy (hirudotherapy) has been attempted in plastic and reconstructive surgery to improve venous congestion in ischemic flaps; however, there are minimal reports related to ischemia secondary to arterial malperfusion. We evaluated a pediatric cohort from an academic intensive care unit with refractory limb ischemia in whom hirudotherapy was attempted to elucidate its use and outcomes.Method: Institutional patient database was queried to identify pediatric patients (<18 years) who received hirudotherapy in the pediatric critical care unit and met inclusion/exclusion criteria. Patient charts were evaluated for indices including demographics, primary disease, coagulative status, vascular access, vasoactive medication dosing, bleeding, leech use, limb and mortality outcomes. Data was evaluated to identify trends or suspected impact on outcomes.Results: Hirudotherapy was used in 7 patients for limb ischemia, 5 with congenital heart disease, and 2 others with viremic shock. Time to leech application following recognition of ischemia averaged 3 days, with duration of use averaging 3.9 days. Five patients discontinued therapy due to bleeding. Mortality rate was 57%, all secondary to multiorgan failure. In 3 surviving patients, 4 of 5 treated limbs resulted in at minimum partial amputation. Vasoactive-inotropic score tended higher prior to leech application, suggesting a vasoconstrictive pathway for arterial malperfusion. No identifiable trends appeared associated with salvaged limb or adverse effects. Blood loss predictably increased with leech application, as did total transfusion requirement.Conclusion: This case series establishes baseline data for use of hirudotherapy in critically ill children with acute limb ischemia caused by arterial malperfusion. Based on this retrospective cohort, we cannot recommend routine use of hirudotherapy for acute limb ischemia from arterial malperfusion in the pediatric intensive care unit. Application of leeches should be aligned with a protocol defining start and stop parameters, standardized leech utilization, and monitoring for adverse outcomes. Future study would benefit from consensus definitions of study outcomes, including perfusion recovery, tissue/limb salvage and bleeding manifestations. Additional prospective studies are needed prior to any standard or systematic recommendations for use.